StemCell Therapy

For the optimal performance of CriPec nanomedicines, it is essential to be able to attach a broad range of small molecule active agents and large molecular entities, biologics, to CriPec nanoparticles.

The published research1reports the development of a convenient and versatile fast-reacting molecular entity for gluing very different compounds in a strain-promoted azide-alkyne cycloaddition click reaction to the nanoparticles, as well as a collection of linkers to attach the widely varying active small molecules and biologics. Next to the already demonstrated examples, many additional applications are foreseen such as the construction of antibody drug conjugates in aqueous environments with faster kinetics that is essential for these delicateconstructs.

CliCr is also used to generate virus mimicking nanoparticles. CriVac is a unique antigen carrier platform based on CriPec nanoparticles that, in contrast to viral vectors, do not convey a bystander immune response. CriPec particles' size resemble a virus and the desired numbers of antigen displayed on its surface are controlled via CliCr. CriVac mimics features of a live virus in a tailored manner to induce immunity safely, efficiently and solely to the displayed antigen, offering a prophylactic vaccination strategy which will be readily adaptable to different pathogenic treats.

The very attractive functionalisation possibilities, combined with its versatility, great reactivity and small size offer multiple opportunities for CliCrreagents to become the new standard for non-copper catalyzed click reactions in a multitude of applications.

Dr Cristianne Rijcken, CSO of Cristal Therapeutics, stated:

"This new versatile click reagent originates from an intense collaboration between industry and academic partners. For our nanomedicine applications, a fast, cleanly reacting and small click reagent is absolutely indispensable. These demands required the development of a new reagent, which will be highly attractive both for our proprietary applications and for the wider world of the biological, medical and material science applications. This is ground-breaking technology!"

In case you are interested to learn about the CliCr platform, please reach out to http://www.clicr.euor talk to us at the following virtual conferences

Reference

1. J. Weterings et al. TMTHSI, a superior 7-membered ring alkyne containing reagent for strain-promoted azidealkyne cycloaddition reactions, Chemical Science (2020)

https://pubs.rsc.org/en/content/articlehtml/2020/sc/d0sc03477k

About Cristal Therapeutics

Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company's product candidates are based on its proprietary CriPec polymeric nanoparticle technology platform, which enables the design of customized nanomedicines with superior therapeutic profiles. CriPec-based products have the potential to provide enhanced efficacy and reduced side effect profiles, thus offering improved disease treatment.

Find out more: http://www.cristaltherapeutics.com

For more information, please contact:

Cristal Therapeutics Jeroen van EgmondConsultant Business DevelopmentT: +31 6 272 048 89E: [emailprotected]

SOURCE Cristal Therapeutics

Read more:
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr technology platform, comprising a new class of superior copper free click...

This entry was posted on October 2, 2020 at 10:53 am and is filed under Nano medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |